Growth Metrics

Arcturus Therapeutics Holdings (ARCT) Income towards Parent Company (2018 - 2025)

Historic Income towards Parent Company for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' Income towards Parent Company fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 656.73%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Income towards Parent Company of -$13.4 million as of Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Income towards Parent Company high stood at $118.6 million for Q4 2022, and its period low was -$57.7 million during Q1 2021.
  • For the 5-year period, Arcturus Therapeutics Holdings' Income towards Parent Company averaged around -$17.9 million, with its median value being -$21.6 million (2022).
  • In the last 5 years, Arcturus Therapeutics Holdings' Income towards Parent Company tumbled by 50944.83% in 2021 and then surged by 41516.0% in 2022.
  • Arcturus Therapeutics Holdings' Income towards Parent Company (Quarter) stood at -$37.6 million in 2021, then surged by 415.16% to $118.6 million in 2022, then plummeted by 109.84% to -$11.7 million in 2023, then crashed by 156.89% to -$30.0 million in 2024, then surged by 55.18% to -$13.4 million in 2025.
  • Its Income towards Parent Company stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.